HOOK HOOKIPA Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HOOK

Price (delayed)

$0.559

Market cap

$46.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.82

Enterprise value

-$56.89M

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.

Highlights
HOOKIPA Pharma's gross profit has surged by 99% YoY and by 29% QoQ
The revenue has soared by 99% YoY and by 29% QoQ
HOOK's quick ratio is down by 29% YoY and by 4.5% from the previous quarter
The company's equity fell by 16% YoY and by 15% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.hookipapharma.com
Peers: OGN

Key stats

What are the main financial stats of HOOK
Market
Shares outstanding
83.95M
Market cap
$46.93M
Enterprise value
-$56.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.49
Price to sales (P/S)
2.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.77
Earnings
Revenue
$20.55M
EBIT
-$68.26M
EBITDA
-$65.09M
Free cash flow
-$37.5M
Per share
EPS
-$0.82
Free cash flow per share
-$0.45
Book value per share
$1.13
Revenue per share
$0.24
TBVPS
$1.95
Balance sheet
Total assets
$164.01M
Total liabilities
$68.96M
Debt
$3.85M
Equity
$95.05M
Working capital
$98.9M
Liquidity
Debt to equity
0.04
Current ratio
3.44
Quick ratio
3.22
Net debt/EBITDA
1.6
Margins
EBITDA margin
-316.7%
Gross margin
100%
Net margin
-336.1%
Operating margin
-391.2%
Efficiency
Return on assets
-40.1%
Return on equity
-70.2%
Return on invested capital
-356.9%
Return on capital employed
-55.3%
Return on sales
-332.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HOOK stock price

How has the HOOKIPA Pharma stock price performed over time
Intraday
5.89%
1 week
12.47%
1 month
30%
1 year
-46.25%
YTD
-30.99%
QTD
-9.25%

Financial performance

How have HOOKIPA Pharma's revenue and profit performed over time
Revenue
$20.55M
Gross profit
$20.55M
Operating income
-$80.39M
Net income
-$69.07M
Gross margin
100%
Net margin
-336.1%
HOOKIPA Pharma's gross profit has surged by 99% YoY and by 29% QoQ
The revenue has soared by 99% YoY and by 29% QoQ
The net margin has surged by 53% year-on-year and by 22% since the previous quarter
The operating margin has surged by 51% year-on-year and by 21% since the previous quarter

Growth

What is HOOKIPA Pharma's growth rate over time

Valuation

What is HOOKIPA Pharma stock price valuation
P/E
N/A
P/B
0.49
P/S
2.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.77
The EPS has grown by 46% YoY and by 9% from the previous quarter
The P/B is 69% below the 5-year quarterly average of 1.5 and 6% below the last 4 quarters average of 0.5
The company's equity fell by 16% YoY and by 15% QoQ
The revenue has soared by 99% YoY and by 29% QoQ
The price to sales (P/S) is 79% lower than the 5-year quarterly average of 10.2 and 23% lower than the last 4 quarters average of 2.8

Efficiency

How efficient is HOOKIPA Pharma business performance
The company's return on invested capital has shrunk by 72% YoY and by 17% QoQ
The ROS has soared by 53% YoY and by 22% from the previous quarter
HOOKIPA Pharma's return on equity has decreased by 15% YoY and by 6% QoQ
The ROA is up by 12% YoY

Dividends

What is HOOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HOOK.

Financial health

How did HOOKIPA Pharma financials performed over time
The total assets is 138% more than the total liabilities
The total liabilities has surged by 81% year-on-year but it has declined by 12% since the previous quarter
HOOKIPA Pharma's current ratio has decreased by 31% YoY and by 5% from the previous quarter
The debt is 96% smaller than the equity
The debt has declined by 38% year-on-year and by 10% since the previous quarter
HOOKIPA Pharma's debt to equity has decreased by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.